ClinicalTrials.gg
RecruitingNCT06999980Neo IRENIEUpdated Feb 19, 2026

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

A Phase 2 interventional study of Ipilimumab 3mg/kg and nivolumab 1mg/kg and Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg in Cutaneous Melanoma and Mucosal Melanoma, sponsored by Melanoma Institute Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Melanoma Institute Australia · Phase 2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.

Planned enrollment
8th of 152
494 · median 30
Started
2026
with 8 others
Phase 2
83 of 155
12 open now
Primary completion
2028-03
later than 31 of 41 live
Registered
147th of 155
by date

Among the 155 studies testing ipilimumab in Melanoma, this one is the 8th largest by planned enrollment of the 152 interventional ones that give a count, is one of 9 that started in 2026, is one of 83 in phase 2, reaches primary completion later than 31 of the 41 other live ones, and was the 147th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing ipilimumab in Melanoma, or all of them as a file.
02

Study summary

This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.

Read the detailed description

This clinical trial is for patients with cutaneous melanoma which has spread to the lymph nodes (known as stage 3 melanoma) and for patients with any stage of mucosal melanoma. The study is for those patients who have disease that can be surgically removed.

The standard treatment for these patients is surgery to remove the affected tumour, lymph nodes, and any other deposits of melanoma, followed by drug therapy (known as adjuvant therapy). The most common drug therapy used to treat melanoma after surgery is known as 'immunotherapy'. Immunotherapy works by boosting the body's own immune system to better recognise and kill cancer cells.

The aim of the study is to offer new immunotherapy combinations to 3 cohorts of patients who are known to be poor responders to standard immunotherapy regimens.

Three cohorts of patients will be included:

  1. Patients with resectable stage 3 cutaneous melanoma who have a predictive biomarker test result that indicates:

    Cohort 1a - they will be poor responders to standard anti-PD-1 immunotherapy (n=168) Cohort 1b - they will be high responders to standard anti-PD-1 immunotherapy (n=\~154)

  2. Patients with resectable stage 3 cutaneous melanoma who have had a recurrence of melanoma despite having standard anti-PD-1 based immunotherapy (n=111).
  3. Patients with resectable mucosal melanoma, at any stage of disease. Mucosal melanoma is known to respond poorly to stabdard immunotherapy (n=60).

This research will test 6 combinations of immunotherapy which are given before surgery. Treatment given before surgery is known as 'neoadjuvant' treatment. Neoadjuvant treatment is standard for many cancers, including melanoma. The purpose of neoadjuvant immunotherapy is to increase the body's natural immune response by training it to recognise the evasive cancer cells before they are removed at surgery, and to shrink or destroy the melanoma, which may make surgery easier. This has been shown to reduce the chance of melanoma recurring after surgery. The drugs used in this study are called 'nivolumab', 'relatlimab', and 'ipilimumab' and 'pembrolizumab'

In this trial, there are 5 different study treatment combinations. Each combination uses different mechanisms to potentially overcome the predicted resistance to standard immunotherapy. There are 4 phases to the study:

  1. Neoadjuvant treatment with one of the new immunotherapy combinations
  2. Surgery
  3. Adjuvant treatment with standard immunotherapy, IF the neoadjuvant therapy has not been effective enough to clear more than 10% of cancer cells.
  4. Follow up for recurrence and survival to the end of 10 years

The main goal is to learn which of the new immunotherapy combinations are most effective at destroying the melanoma cells before surgery for each cohort of patients.

The other important goals are to learn which treatment is best at preventing the return of melanoma over 10 years and which increases survival from melanoma. The investigators also want to evaluate the side effects patients may have to treatment and how this affects the quality of life. The investigators will also continue to research biomarkers in blood, tumour tissue and stools to identify possible mechanisms for better response to therapy.

The study will be conducted in Australia and a total of 493 patients will be involved.

03

Conditions studied

  • Cutaneous Melanoma
  • Mucosal Melanoma

Browse trials for

Keywords

  • Neoadjuvant
  • Immunotherapy
  • Randomised trial
  • Low Responder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

COMMON Inclusion Criteria Applicable to all 3 cohorts

Inclusion Criteria:

  • 1. Written
  • 2. Male or female patients who are at least 18 years of age on the day of signing informed consent.
  • 3. Clinically detectable disease, and/or version 1.1 defined disease, and/or disease confirmed on PET imaging.
  • 4. Fully resectable disease defined as having no significant vascular, central nervous system or bony involvement. Only cases where a complete surgical resection leading to tumour free margins and which is safely achieved is considered "resectable".
  • 5. Concurrent primary disease and lymph node acceptable provided completely resectable.
  • 6. Up to 3 in-transit metastases are permitted as long as these are fully resectable.
  • 7. Tumour that is amenable to a newly obtained core for performance of the multi-omic predictive biomarker model
  • 8. performance status of 0 to 1.
  • 9. Adequate haematological, hepatic, renal and endocrine function
  • 10. An anticipated of >12 months.
  • 11. Women of child bearing potential () must agree to avoid pregnancy or breast feeding for the duration of study treatment.

Inclusion Criteria - Cohort 1 only

  • a. confirmed diagnosis of cutaneous melanoma or unknown primary melanoma
  • b. AJCC 8th Ed Stage IIIB, IIIC, IIID cutaneous melanoma
  • c. No prior systemic treatment for cutaneous melanoma
  • d. Completion of the multi-omic predictive biomarker model within 14 days (7-10 business days) of planned randomisation.

Inclusion Criteria - Cohort 2 only

  • a. Histologically confirmed diagnosis of cutaneous melanoma or unknown primary melanoma
  • b. AJCC 8th Ed Stage IIIB, IIIC, IIID cutaneous melanoma
  • c. Disease progression on monotherapy, where progressed disease is completely resectable or, disease recurrence on adjuvant anti-PD-1 monotherapy, where recurrent disease is completely resectable
  • d. No prior treatment with CTLA-4 or LAG-3 inhibitors.

Inclusion Criteria - Cohort 3 only

  • a. Histologically confirmed diagnosis of mucosal melanoma
  • b. Any stage of disease provided it is fully resectable
  • c. No prior systemic treatment for mucosal melanoma

COMMON Exclusion Criteria Applicable to all 3 cohorts

  • 1. Uveal melanoma
  • 2. Any to the administration of relatlimab, ipilimumab or nivolumab
  • 3. No prior systemic therapy, including treatment with prior anti-PD1/L1, anti-CTLA-4 or anti-LAG-3 therapy (cohorts 1 and 3), except for cohort 2 which will have received anti-PD1 monotherapy only.
  • 4. A diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 14 days of randomisation. The following are permitted:

    1. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc)
    2. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient is on a stable dose
    3. Non-absorbed intra-articular steroid injections.
  • 5. An active disease that has required systemic treatment in the past 12 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). The following are permitted:

    1. Vitiligo
    2. Type I diabetes mellitus
    3. Residual autoimmune hypothyroidism on stable hormone replacement
    4. Resolved childhood asthma or atopy
    5. Psoriasis not requiring systemic treatment
    6. Autoimmune conditions which are not expected to recur in the absence of an external trigger.
  • 6. A known additional that is progressing or has required active treatment within the past 3 years. The following malignancies, if undergone successful definitive resection or curative treatment, are permitted:

    1. Basal cell carcinoma of the skin
    2. Squamous cell carcinoma of the skin
    3. Carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy)
    4. Prostatic intraepithelial neoplasia
    5. In situ melanoma
    6. Atypical melanocytic hyperplasia
    7. Multiple primary melanomas
    8. Other malignancies for which the patient has been disease free for 1 year.
  • 7. A known and/or carcinomatous meningitis
  • 8. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis or current interstitial lung disease.
  • 9. Has an active infection requiring systemic therapy.
  • 10. Has a known history of (HIV). Note: no testing for HIV is required unless mandated by local health authority.
  • 11. Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  • 12. Has a known history of active TB (Bacillus Tuberculosis).
  • 13. Uncontrolled or significant cardiovascular disease including, but not limited to any of the following:

    1. Myocardial infarction (MI) or stroke/ within the 6 months prior to consent
    2. Uncontrolled angina within the 3 months prior to consent
    3. Any history of arrhythmias (such as poorly controlled atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    4. prolongation > 480 ms
    5. History of other clinically significant cardiovascular disease (i.e. cardiomyopathy, congestive heart failure with functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled venous thrombosis, etc)
    6. Cardiovascular disease-related requirement for daily supplemental oxygen
    7. History of 2 or more M.I.s OR 2 or more coronary revascularisation procedures (regardless of the number of stent placements during each procedure)
    8. Patients with history of myocarditis, regardless of aetiology.
  • 14. Patients with a >1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \<1 g/24 hours.
  • 15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  • 16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • 17. Pregnant or breast feeding females
  • 18. Concurrent medical or social conditions that may prevent the patient from attending assessments per schedule
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
494 participants (estimated)

Study arms

  • Experimental
    Treatment Arm A

    Ipilimumab at 3 mg per kg with nivolumab at 1 mg per kg will be administered on days 1 and 22 (Q3W) in the neoadjuvant period for a total of 2 doses.

    Drug: Ipilimumab 3mg/kg and nivolumab 1mg/kg

  • Experimental
    Treatment Arm B

    Ipilimumab 1mg per kg and the fixed dose combination nivolumab 480 mg and relatlimab 160 mg will be administered on days 1 and 29 (Q4W) for a total of 2 doses.

    Drug: Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg

  • Experimental
    Treatment Arm C

    Fixed dose combination of nivolumab 480 mg and relatlimab 160 mg alone, to be administered on days 1 and 29 (Q4W) for a total of 2 doses.

    Drug: Nivolumab 480mg and relatlimab 160mg

  • Active comparator
    Treatment Arm D (Cohort 1a)

    Ipilimumab at 1 mg per kg with nivolumab at 3 mg per kg will be administered on days 1 and 22 (Q3W) in the neoadjuvant period for a total of 2 doses.

    Drug: Ipilimumab 1mg/kg and nivolumab 3mg/kg

  • Active comparator
    Treatment Arm E (Cohort 1b)

    Ipilimumab at 1 mg per kg with nivolumab at 3 mg per kg will be administered on days 1 and 22 (Q3W) in the neoadjuvant period for a total of 2 doses.

    Drug: Ipilimumab 1mg/kg and nivolumab 3mg/kg

  • Active comparator
    Treatment Arm F

    Pembrolizumab 200 mg will be administered on days 1 and 22 (Q3W) in the neoadjuvant period for a total of 2 doses

    Drug: Pembrolizumab 200 mg

Interventions

  • DrugIpilimumab 3mg/kg and nivolumab 1mg/kg

    Drug page: IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant for 2 doses on days 1 and 22

    Also known as: Arm A

  • DrugIpilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg

    Drug page: IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant for 2 doses at days 1 and 29

    Also known as: Arm B

  • DrugNivolumab 480mg and relatlimab 160mg

    Drug page: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant for 2 doses on days 1 and 29

    Also known as: Arm C

  • DrugIpilimumab 1mg/kg and nivolumab 3mg/kg

    Drug page: IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant for 2 doses at days 1 and 22

    Also known as: Arm D (Cohort 1a)

  • DrugPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant for 2 doses at days 1 and 22

    Also known as: Arm F

06

What researchers measure

Primary outcomes

  1. Pathological response rate

    The primary endpoint is the pathological response rate at surgery (between days 43 and 56) from the first dose of neoadjuvant study treatment for each of cohorts 1b, 2 and 3. The pathological response is categorised thus: - Complete pathological response (pCR) - 0% viable tumour cells in the surgical specimen - Near complete pathological response - (near pCR) - \<10% viable tumour - Partial pathological response (pPR) - 10%-50% viable tumour - No pathological response (pNR) - \>50% viable tumour The proportion of participants with a pCR, or near pCR will determine the pathological response rate.

    Time frame: Week 6

Secondary outcomes

  1. Event-free survival (EFS)

    The proportion of patients with the earliest EFS outcome of: (a) Melanoma progression from randomisation and prior to planned surgery (b) Disease recurrence, from the date of surgery (local, regional or distant). (c) Study treatment-related death from randomisation. (d) Melanoma-related death, from randomisation.

    Time frame: 10 years

  2. Objective response rate

    RECIST version 1.1 defined objective response at week 6 for patients with RECIST-measurable disease at baseline

    Time frame: Week 6

  3. Metabolic response rate

    PERCIST defined metabolic response

    Time frame: Week 6

  4. Loco-regional relapse-free survival

    Time from surgery to the date of loco-regional recurrence

    Time frame: 10 years

  5. Distant metastases-free survival

    Time from surgery to the earliest date of distant recurrence, treatment-related death, or melanoma-related death

    Time frame: 10 years

  6. Overall survival

    Time from randomisation to death

    Time frame: at 1, 2, 5 and 10 years

  7. Type, frequency and severity of drug-related toxicities

    The number, type, and grade of treatment-related adverse events per CTCAE version 5.0

    Time frame: 30 days from last dose of study treatment

  8. Surgical adverse outcomes

    The number and grade of surgical complications according to the Clavien-Dindo Classification assessed at 3, 12 and 48 weeks post-operatively

    Time frame: At 3, 12 and 48 weeks post-operatively

  9. Health related quality of life

    The individual, summary and composite scores obtained from the validated EUROQOL QLQ-C30, EQ-5D, FACT-M (questions M10 to M17)

    Time frame: 1 year

  10. Comparison of the actual pathologocal response to each immunotherapy arm with the predicted pathological response to neoadjuvant immunotherapy based on the multi-omic predictive biomarker model

    Correlation of the actual pathological response with the predicted response to combination neoadjuvant immunotherapy based on the multi-omic predictive biomarker model

    Time frame: Week 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 25 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
May 31, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jan 2038
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999980
Lead sponsor
Melanoma Institute Australia
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Feb 9, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jan 2038 (estimated)
Last update
Feb 19, 2026

Study contacts

Monica Osorio
Contact
Monica.Osorio@melanoma.org.au
+612 9911 7296
Georgina Long
study chair · Melanoma Institute Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion